上海医药:盐酸维拉帕米注射液通过仿制药一致性评价

南方财经网
Sep 01

  南财智讯9月1日电,上海医药公告,下属上海禾丰制药有限公司收到国家药监局关于盐酸维拉帕米注射液的仿制药质量和疗效一致性评价结果,该药品通过了一致性评价。该药品主要用于快速阵发性室上性心动过速的转复和心房扑动或心房颤动心室率的暂时控制。通过一致性评价后,该药品有望在医保支付及医疗机构采购等领域获得更大支持,有利于扩大市场份额和提升市场竞争力。然而,由于国家政策和市场环境的不确定性,该药品的销售存在一定的风险。

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10